JUN 23, 2020 3:24 PM PDT

Psychedelic DMT to Enter Clinical Trials

WRITTEN BY: Annie Lennon

Neuro-pharmaceutical company, MindMed, has announced that it will begin a double-blind placebo-controlled Phase 1 clinical trial to understand how N, N-Dimethyltryptamine (DMT), the primary psychoactive ingredient in Ayahuasca, works in the body. The company ultimately hopes to create therapeutics with the substance to treat mental health conditions like depression and addiction. 

“There is a growing trend in Western society to use Ayahuasca and DMT to facilitate a healing process for one’s mind. However, there is very limited safety data and clinical trials evaluating DMT as a potential medicine so we are going to double down on understanding the therapeutic opportunity and more effective ways to administer DMT in a controlled setting to achieve this healing process.” says JR Rahn, cofounder of MindMed. 

There are currently no approved clinical uses for DMT. The substance has nevertheless been used for centuries, if not longer, by various civilizations and tribes around the world for both its mentally restorative and explorative effects. In the first clinical trial of its kind, the researchers want to establish whether the substance could be engineered for future drug development programs to treat conditions like addiction. 

In partnership with the University Hospital Basel’s Liechti Lab, the researchers from MindMed thus plan to conduct experiments in which patients receive DMT intravenously. Quickly metabolized if taken orally, taking DMT intravenously means that the researchers will both be able to ensure continuous application of the substance, and thus a prolonged DMT experience.

It also means they will be able to stop administration of the substance and the ensuing DMT experience quickly should anything go wrong. In this way, the researchers hope to establish proper dosing during the trial with the goal of inducing a stable DMT experience of between an hour and two hours among patients. 

The study is expected to begin in late 2020, from which the researchers hope to lay the foundations for a future Phase II clinical proof of concept trials. 

 

Sources: MindMed, Bezinga

 

About the Author
  • Science writer with a keen interest in behavioral biology, consciousness medicine and technology. Her current focus is how the interplay of these fields can create meaningful interactions, products and environments.
You May Also Like
JUN 21, 2021
Cardiology
Researchers Find Evidence That Gut Microbes Affect Stroke Severity
JUN 21, 2021
Researchers Find Evidence That Gut Microbes Affect Stroke Severity
Research has indicated that there is a connection between gut microbes and heart health. Now scientists are revealing so ...
JUL 05, 2021
Drug Discovery & Development
ADHD Drug Reduces Daydreaming, Fatigue and Boredom
JUL 05, 2021
ADHD Drug Reduces Daydreaming, Fatigue and Boredom
Researchers led by New York University have found that a stimulant drug may be able to treat persistent daydreaming, fat ...
JUL 23, 2021
Cancer
New Drug Eradicates Breast Cancer Tumors in Days
JUL 23, 2021
New Drug Eradicates Breast Cancer Tumors in Days
A new drug can kill between 95 and 100% of cancer cells in mice with human estrogen-receptor-positive breast cancer. The ...
AUG 21, 2021
Neuroscience
Is Humor the Best Way to Deliver Public Health Interventions?
AUG 21, 2021
Is Humor the Best Way to Deliver Public Health Interventions?
Humor is an effective way to deliver public health interventions and influence people’s behavior around their heal ...
AUG 26, 2021
Microbiology
Some Herbal Medicines May Help Treat Tick-Borne Diseases
AUG 26, 2021
Some Herbal Medicines May Help Treat Tick-Borne Diseases
Ticks are vectors for disease; they can transmit pathogenic bacteria to animals and humans through their bites. Diseases ...
SEP 12, 2021
Coronavirus
Real-World, Post-Delta COVID-19 Vaccine Data & Potential Treatment
SEP 12, 2021
Real-World, Post-Delta COVID-19 Vaccine Data & Potential Treatment
New research may have identified a potential treatment or preventive medication for SARS-CoV-2 and other viral infection ...
Loading Comments...